The kidneys play a big part in controlling blood pressure. In fact, many of the major hypertensive medications have the root of their actions located in the kidneys. Diuretics work there, ACE inhibitors work there, as do the ARB’s, Spironolactone, and Triamterene.
Over the past 18-20 months we have been using the SGLT-2 inhibitors to lower glucose, and in many of these diabetes patients weight loss has been a bonus. These drugs also have their mechanism of action in the kidney, and seem to work by causing patients to eliminate the extra glucose that is reabsorbed because of the diabetes defect. With more than 7 million prescriptions filled for the class, we are seeing another benefit of this elimination of glucose: lower blood pressure levels. This month our issue is dedicated to understanding the possible role of SGLT-2 inhibitors in reducing blood pressure and improving cardiovascular health.
Your partner in diabetes care,
New studies indicate potential class effect in reducing hypertension.
New study shows benefit for patients receiving calcium channel blocker or beta-blocker.
Various T2 factors create need for multiple treatment options.
To maintain the benefits while minimizing risk, consider patient risk factors when prescribing, and monitor for DKA and UTI.
Jan 21, 2016 : Latest SGLT-2 Inhibitors News
A Possible Role for SGLT-2 Inhibitors in Blood Pressure Control
New studies indicate potential class effect in reducing hypertension.Read More
Dapagliflozin Significantly Improves Blood Pressure
New study shows benefit for patients receiving calcium channel blocker or beta-blocker.Read More
Where Do SGLT-2 Inhibitors Fit in Diabetes Care?
Various T2 factors create need for multiple treatment options.Read More
Assessing the Latest Information on SGLT-2 Inhibitors and Ketoacidosis
To maintain the benefits while minimizing risk, consider patient risk factors when prescribing, and monitor for DKA and UTI.Read More